No abstract

No abstract

against PDL1. Growth pattern of RenCa/sh-PD-L1 with or without sunitinib was compared with that of RenCa cells transfected with control plasmid alone (RenCa/Co).RESULTS: No significant difference in growth or sensitivity to sinitinib was noted between RenCa/sh-PD-L1 and RenCa/Co cells in vitro. The tumor volume in mice subcutaneously injected with RenCa/sh-PD-L1 was significantly smaller than that with RenCa/Co. Treatment of mice bearing each tumor with sunitinib resulted in a significant reduction of the RenCa/sh-PD-L1 tumor compared with RenCa/Co tumor. Moreover, infiltration by CD8þ T cells of RenCa/sh-PD-L1 tumors was significantly higher than that of RenCa/Co tumors, irrespective of treatment with sunitinib. While, infiltration by CD4þ T cells and Foxp3þ T cells showed no difference between RenCa/sh-PD-L1 and RenCa/Co tumors, irrespective of treatment with sunitinib.CONCLUSIONS: Suppressed expression of PD-L1 could increase tumorinfiltrating CD8þ T cells and result in growth inhibition as well as enhanced sensitivity to sunitinib in the RenCa model.

No abstract

No abstract